Epidemiology, natural history and pathogenesis of hepatocellular carcinoma;Épidémiologie, histoire naturelle et pathogenèse du carcinome hépatocellulaire

Cancer/Radiotherapie

Volumn 15, Issue 1, 2011, Pages 3-6

  Maillard, E ^a  

^a HÔTEL DIEU   (France)

Author keywords

Epidemiology; Hepatitis viruses; Hepatocellular carcinoma; Oncogenesis

Indexed keywords

ALCOHOL CONSUMPTION; APOPTOSIS; CANCER EPIDEMIOLOGY; CANCER MORTALITY; CANCER RISK; CANCER SCREENING; CELL DIFFERENTIATION; CELL GROWTH; CELL MOTILITY; CHRONIC INFLAMMATION; DISEASE ASSOCIATION; ECHOGRAPHY; EPIGENETICS; FRANCE; HEMOCHROMATOSIS; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS VIRUS; HOMEOSTASIS; HUMAN; INTRACELLULAR SIGNALING; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER REGENERATION; NONHUMAN; PRECANCER; PRIORITY JOURNAL; SHORT SURVEY; VIRUS CARCINOGENESIS; VIRUS GENOME;

CARCINOMA, HEPATOCELLULAR; HEPATITIS; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; ONCOGENIC VIRUSES;

EID: 79551529061     PISSN: 12783218     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canrad.2010.11.010     Document Type: Short Survey

References (36)

1. Parkin D.M., Bray F., Ferlay J., Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001, 94:153-156.
2. Bosch F.X., Ribes J., Cleries R., Diaz M. Epidemiology of hepatocellular carcinoma. Clin Liver Dis 2005, 9:191-211. [v].
3. Yuen M.F., Hou J.L., Chutaputti A. Hepatocellular carcinoma in the Asia pacific region. J Gastroenterol Hepatol 2009, 24:346-353.
4. McGlynn K.A., London W.T. Epidemiology and natural history of hepatocellular carcinoma. Best Pract Res Clin Gastroenterol 2005, 19:3-23.
5. Chang M.H., Chen C.J., Lai M.S., Hsu H.M., Wu T.C., Kong M.S., et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. N Engl J Med 1997, 336:1855-1859.
6. Maddrey W.C., Hepatitis B An important public health issue. J Med Virol 2000, 61:362-366.
7. Mindikoglu A.L., Miller R.R. Hepatitis C in the elderly: epidemiology, natural history, and treatment. Clin Gastroenterol Hepatol 2009, 7:128-134. quiz 124.
8. Kawada N., Imanaka K., Kawaguchi T., Tamai C., Ishihara R., Matsunaga T., et al. Hepatocellular carcinoma arising from non-cirrhotic nonalcoholic steatohepatitis. J Gastroenterol 2009, 44:1190-1194.
9. Schlichting P., Christensen E., Fauerholdt L., Poulsen H., Juhl E., Tygstrup N. Main causes of death in cirrhosis. Scand J Gastroenterol 1983, 18:881-888.
10. Ikeda K., Saitoh S., Koida I., Arase Y., Tsubota A., Chayama K., et al. A multivariate analysis of risk factors for hepatocellular carcinogenesis: a prospective observation of 795 patients with viral and alcoholic cirrhosis. Hepatology 1993, 18:47-53.
11. Deuffic S., Poynard T., Buffat L., Valleron A.J. Trends in primary liver cancer. Lancet 1998, 351:214-215.
12. Law M.G., Dore G.J., Bath N., Thompson S., Crofts N., Dolan K., et al. Modelling hepatitis C virus incidence, prevalence and long-term sequelae in Australia, 2001. Int J Epidemiol 2003, 32:717-724.
13. Trinchet J.C., Beaugrand M. Augmentation de l'incidence du carcinome hépatocellulaire dans les pays occidentaux. Gastroenterol Clin Biol 1999, 23:1286-1288.
14. Deuffic S., Buffat L., Poynard T., Valleron A.J. Modeling the hepatitis C virus epidemic in France. Hepatology 1999, 29:1596-1601.
15. Zhao M., Zhang N.X., Laissue J.A., Zimmermann A. Immunohistochemical analysis of p53 protein overexpression in liver cell dysplasia and in hepatocellular carcinoma. Virchows Arch 1994, 424:613-621.
16. Libbrecht L., Desmet V., Roskams T. Preneoplastic lesions in human hepatocarcinogenesis. Liver Int 2005, 25:16-27.
17. Maggioni M., Coggi G., Cassani B., Bianchi P., Romagnoli S., Mandelli A., et al. Molecular changes in hepatocellular dysplastic nodules on microdissected liver biopsies. Hepatology 2000, 32:942-946.
18. Sun M., Eshleman J.R., Ferrell L.D., Jacobs G., Sudilovsky E.C., Tuthill R., et al. An early lesion in hepatic carcinogenesis: loss of heterozygosity in human cirrhotic livers and dysplastic nodules at the 1p36-p34 region. Hepatology 2001, 33:1415-1424.
19. Tornillo L., Carafa V., Sauter G., Moch H., Minola E., Gambacorta M., et al. Chromosomal alterations in hepatocellular nodules by comparative genomic hybridization: high-grade dysplastic nodules represent early stages of hepatocellular carcinoma. Lab Invest 2002, 82:547-553.
20. Lencioni R., Crocetti L. Della Pina MC. Cioni D. Guidelines for imaging focal lesions in liver cirrhosis. Expert Rev Gastroenterol Hepatol 2008, 2:697-703.
21. Boyault S., Rickman D.S., de Reynies A., Balabaud C., Rebouissou S., Jeannot E., et al. Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Hepatology 2007, 45:42-52.
22. Lee J.S., Thorgeirsson S.S. Genome-scale profiling of gene expression in hepatocellular carcinoma: classification, survival prediction, and identification of therapeutic targets. Gastroenterology 2004, 127:S51-S55.
23. Hoshida Y., Nijman S.M., Kobayashi M., Chan J.A., Brunet J.P., Chiang D.Y., et al. Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. Cancer Res 2009, 69:7385-7392.
24. Thomas R.M., Berman J.J., Yetter R.A., Moore G.W., Hutchins G.M. Liver cell dysplasia: a DNA aneuploid lesion with distinct morphologic features. Hum Pathol 1992, 23:496-503.
25. Buendia M.A. Genetics of hepatocellular carcinoma. Semin Cancer Biol 2000, 10:185-200.
26. de La Coste A., Romagnolo B., Billuart P., Renard C.A., Buendia M.A., Soubrane O., et al. Somatic mutations of the beta-catenin gene are frequent in mouse and human hepatocellular carcinomas. Proc Natl Acad Sci U S A 1998, 95:8847-8851.
27. Taniguchi K., Roberts L.R., Aderca I.N., Dong X., Qian C., Murphy L.M., et al. Mutational spectrum of beta-catenin. AXIN1, and AXIN2 in hepatocellular carcinomas and hepatoblastomas. Oncogene 2002, 21:4863-4871.
28. Wong C.M., Fan S.T. Ng IO. beta-Catenin mutation and overexpression in hepatocellular carcinoma: clinicopathologic and prognostic significance. Cancer 2001, 92:136-145.
29. Breuhahn K., Longerich T., Schirmacher P. Dysregulation of growth factor signaling in human hepatocellular carcinoma. Oncogene 2006, 25:3787-3800.
30. Chen C.J., Yang H.I., Su J., Jen C.L., You S.L., Lu S.N., et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. Jama 2006, 295:65-73.
31. Chisari F.V., Klopchin K., Moriyama T., Pasquinelli C., Dunsford H.A., Sell S., et al. Molecular pathogenesis of hepatocellular carcinoma in hepatitis B virus transgenic mice. Cell 1989, 59:1145-1156.
32. Kasahara A., Hayashi N., Mochizuki K., Takayanagi M., Yoshioka K., Kakumu S., et al. Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Hepatology 1998, 27:1394-1402.
33. Niederau C., Lange S., Heintges T., Erhardt A., Buschkamp M., Hurter D., et al. Prognosis of chronic hepatitis C: results of a large, prospective cohort study. Hepatology 1998, 28:1687-1695.
34. Sakamuro D., Furukawa T., Takegami T., Hepatitis C virus nonstructural protein NS3 transforms NIH 3T3 cells. J Virol 1995, 69:3893-3896.
35. Ray R.B., Lagging L.M., Meyer K., Ray R., Hepatitis C virus core protein cooperates with ras and transforms primary rat embryo fibroblasts to tumorigenic phenotype. J Virol 1996, 70:4438-4443.
36. Park J.S., Yang J.M., Min M.K. Hepatitis C virus nonstructural protein NS4B transforms NIH3T3 cells in cooperation with the Ha-ras oncogene. Biochem Biophys Res Commun 2000, 267:581-587.